None listed
Conditions
Interventions
Dietary Supplement : This trial is conducted as a randomized, open-label, single -dose, crossover, phase I to evaluate the effect of food on the safety, tolerability and pharmacokinetics of EC-18. EC-
Sponsors
Novotech Asia Korea
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Healthy adult aged between 19 and 45 years, inclusive, at the time of providing the informed consent form 2) body weight: = 55kg(male), = 50kg(female) 3) BMI: 18.5 kg/m2 ? BMI < 25.0 kg/m2 ? BMI(body mass index) = Body weight (kg)/[height (m)]2 4) in female subjects, the result of serum ß-hCG pregnancy test comes out negative at screening, urine ß-hCG test comes out negative before taking medication during the period set by this protocol have to be included one of the below conditions. - postmenopausal(no natural menstruation at least 2 years) - surgically sterile(hysterectomy or bilateral ovariotomy, tubal ligation or sterile condition by other ways) - sterility of male partner before screening(proof the azoospermia after vasectomy), and this is the only parter of the subject. - agree with using a proper and continuous method of contraception start on 14 days(at least) before the1st IND administraion and for 28 days(at least) after the last IND administraion * proper contraception means physical barrier method including condom, contraceptive diaphragm or cervix cap, do not use a hormones including contraceptive or oral contraceptive during the study. 5) if the male have a sex life with childbearing aged female, maintain proper contraception during the study and for 28 days after the last IND administraion, agree with "do not donate the sperm"(if the female partner is infertility, above contraceptions are not necessary) 6) Written consent on voluntary decision of participation and compliance with precautions after being fully informed of and completely understanding this trial
Exclusion criteria
Exclusion criteria: 1) Hypersensitivity to a drug containing an ingredient of the investigational product(EC-18) or similar ingredient (e.g., deer antler) or other drugs (e.g., aspirin, antibiotics) or medical history of clinically significant hypersensitivity 2) Active infection such as chronic or local infection based on screening tests or inquiry, verifiable medical records 3) Serious infection that required hospitalization or use of antibiotics within 30 days prior to the first dose of the investigational product, based on an inquiry or verifiable medical records 4) Presence of a clinically significant hepatic, renal, gastrointestinal, respiratory, musculoskeletal, endocrine, nervous, blood, cardiovascular, urogenital, psychiatric disorder or its prior history 5) (1) Presenting tuberculosis or prior history of tuberculosis or (2) positive results from a QuantiFERON®-TB Gold in Tube Assay conducted due to a contact with a tuberculosis patient within the past 3 months or signs and symptoms of suspected tu berculosis 6) Prior history of a gastrointestinal disorder (e.g., Crohn's disease, ulcer) or surgery (except for simple appendectomy or hernia surgery) that may affect drug absorption, etc.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| evaluate safety and tolerability: ADRs monitoring such as subjective, objective symptom;evaluate safety and tolerability:vital sign;evaluate safety and tolerability: physical examination;evaluate safety and tolerability: clinical laboratory test;evaluate safety and tolerability: EKG | — |
Secondary
| Measure | Time frame |
|---|---|
| evaluate pharmacokinetics: Cmax;evaluate pharmacokinetics: AUClas;evaluate pharmacokinetics: tmax;evaluate pharmacokinetics: AUCinf;evaluate pharmacokinetics: t1/2;evaluate pharmacokinetics: CL/F;evaluate pharmacokinetics: Vd/F | — |
Countries
Korea, Republic of
Contacts
Public ContactHeejung Kim
Yonsei University Health System, Severance Hospital
Outcome results
None listed